We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

7 hedge funds and large institutions have $43.7K invested in Northwest Biotherapeutics, Inc. Common stock in 2025 Q4 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% less funds holding

Funds holding: 9 → 7 (-2)

75% less capital invested

Capital invested by funds: $175K → $43.7K (-$132K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VWA
VSM Wealth Advisory
Maryland
+$2.79K
2
EFG
Ethos Financial Group
Pennsylvania
+$686

Top Sellers

Rank Fund Capital Flow
1
KA
KLCM Advisors
Wisconsin
-$2.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
VWA
1
VSM Wealth Advisory
Maryland
$15K +$2.79K +15,000 +23%
OCG
2
Opus Capital Group
Ohio
$14K – – –
EFG
3
Ethos Financial Group
Pennsylvania
$6.49K +$686 +3,000 +12%
WJWM
4
Williams Jones Wealth Management
New York
$6.18K – – –
AMG
5
Advisors Management Group
Wisconsin
$2K – – –
KA
6
KLCM Advisors
Wisconsin
– -$2.4K -10,000 Closed

NWBO Hedge Fund Activity: Q4 2025 in Review

7 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2025, worth a combined $43.7K — down 75% from $175K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of NWBO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.

The largest buyer was VSM Wealth Advisory, adding an estimated $2.79K. The largest seller was KLCM Advisors, exiting entirely with an estimated $2.4K sold.

  • 7 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2025, down from 9 in Q3 2025.
  • Funds reported $43.7K of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2025, down 75% quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2025 and 1 closed out, a net change of -1 holder.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2025 was VSM Wealth Advisory, an estimated $2.79K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q4 2025 was KLCM Advisors, an estimated $2.4K sold.

Based on aggregated 13F filings for Q4 2025.